Strategy 2025

Marinomed is committed to improving people's health. With our new augmented strategy, we are increasing our focus on high unmet medical needs with the aim to provide important benefits for patients and generate sustainable value for our stakeholders.

Marinomed has the vision to transform the lives of people living with diseases with limited or no treatment options in two key therapeutic areas: virology and immunology.

Coming from a clear OTC focus in the last 15 years, we have decided to expand the applications of iota-carrageenan in the field of viral infectious diseases and focus our Marinosolv-based pipeline on therapies for immune disorders. This decision is based on scientific data, product development success, extensive scientific and industry know-how.

We aim to provide physicians and patients with powerful therapies to significantly improve patients' quality of life. Our two proprietary and validated platforms, Marinosolv and iota-carrageenan, will provide the basis for novel Rx medicines for the treatment of indications with high unmet medical needs.

Our augmented strategy will be supported in-depth market analysis, and continuing engagement with international key opinion leaders.

Learn more about our augmented strategy in our current annual report and investor presentation here.

Lean Business Model

Marinomed’s aim is to achieve long term profitability via the exploitation and commercialization of a strong technology portfolio. Marinomed is already generating revenues from the Carragelose® platform and the sale of its products. During the company’s short history, the Marinomed team has already demonstrated its success in the research, development and marketing of its products.

Marinomed develops biopharmaceutical products on the basis of its technologies in the therapeutic areas of virology and immunology. After obtaining approval (or a declaration of conformity for medical devices), Marinomed’s products are manufactured and sold via partners and licenses. By outsourcing the cost intensive components of the value chain, Marinomed has achieved a lean, asset light business model in tandem with strong growth.

The products are manufactured by various providers on behalf of Marinomed. Its sales partners, most of which are well-known pharmaceutical firms, obtain licenses from Marinomed to sell its products for individual geographical regions. Involving relatively little expenditure, this approach enables the company to supervise and organize partnerships in more than 40 countries on all five continents.